HCV-IN-31 – CAS 1998705-62-6
HCV-IN-31 – CAS 1998705-62-6 is synthesized by Sigut Labs (Prague, Czech Republic).
Purity (LC-MS)
min 95%
Package contents
HCV-IN-31
This compound is for research use only. We do not sell to patients.
Amount
| 10 mg | € 400 | Stock | ||
| 100 mg | € 1500 | Stock | ||
| Do you want custom amount? | Custom amount | |||
Amount
10 mg
€ 400
Stock
100 mg
€ 1500
Stock
Do you want custom amount?
Custom amount
Characterisation
CAS: 1998705-62-6
IUPAC name: (2R,3R,4R,5R)-5-[2-amino-6-(methylamino)purin-9-yl]-4-fluoro-2-(hydroxymethyl)-4-methyloxolan-3-ol
Other names: GLXC-25726, HY-138305
Molecular weight: 312.30 g/mol
Molecular formula: C12H17FN6O3
InChI: InChI=1S/C12H17FN6O3/c1-12(13)7(21)5(3-20)22-10(12)19-4-16-6-8(15-2)17-11(14)18-9(6)19/h4-5,7,10,20-21H,3H2,1-2H3,(H3,14,15,17,18)/t5-,7-,10-,12-/m1/s1
Description
HCV-IN-31 is an HCV inhibitor, with an EC50/EC95 of 15.7 μM for HCV replicon. It is a parent nucleoside of the drug Bemnifosbuvir.
Chemicals are distributed worldwide
Buy HCV-IN-31 now, and get your order in 48 hours
- Shipping through DHL in 48 hours
- Sensitive compounds are shipped on dry ice
- All compounds are safely and rigorously packed
Payment
- Payment terms 30 days net
- We are sending the invoice the same day as the shipment
- We are able to modify the invoice for the academic institution, so the order can be paid from grants
References
- Ben-Ari, Z., Pappo, O., Druzd, T., Sulkes, J., Klein, T., Samra, Z., … & Mor, E. (2004). Role of cytokine gene polymorphism and hepatic transforming growth factor β1 expression in recurrent hepatitis C after liver transplantation. Cytokine, 27(1), 7-14.
- Konstantinou, D., & Deutsch, M. (2015). The spectrum of HBV/HCV coinfection: epidemiology, clinical characteristics, viralinteractions and management. Annals of gastroenterology: quarterly publication of the Hellenic Society of Gastroenterology, 28(2), 221.
- Liu, C. J., Chen, P. J., Lai, M. Y., Kao, J. H., Jeng, Y. M., & Chen, D. S. (2003). Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients. Hepatology, 37(3), 568-576.
Similar products
Didn't find the chemical you were looking for?
Contact us
WHY CHOOSE
SigutLabs
Your impossible is our starting line
Located in Prague, Czech Republic, EU
Versatile, seasoned all-PhD team
Global delivery with Silicon Valley clients
Open communication, reliable approach
Verifying quality of all produced substances
95% shipments delivered within 2 days
Partners & distributors
